
You are here
Consultations
We conduct public consultations as part of our broader stakeholder engagement work, including on changes to regulatory requirements or practices, reviews of business processes, standards or guidelines, and TGA fees and charges.
Trove at the National Library of Australia has information on archived TGA consultations and reviews.
Filters
Status
Categories
- Remove Advertising filter Advertising (2)
- Australian Register of Therapeutic Goods (ARTG) (1) Apply Australian Register of Therapeutic Goods (ARTG) filter
- Remove Biologicals filter Biologicals (2)
- Complementary medicines (7) Apply Complementary medicines filter
- Remove Cosmetics filter Cosmetics (0)
- Fees/Payments (1) Apply Fees/Payments filter
- Import/Export (1) Apply Import/Export filter
- Remove Labelling/Packaging filter Labelling/Packaging (1)
- Legislation (3) Apply Legislation filter
- Listed medicines (2) Apply Listed medicines filter
- Manufacturing (1) Apply Manufacturing filter
- Medical devices/IVDs (55) Apply Medical devices/IVDs filter
- Medical devices safety (1) Apply Medical devices safety filter
- Medicinal cannabis (1) Apply Medicinal cannabis filter
- Medicines (2) Apply Medicines filter
- Medicines safety (1) Apply Medicines safety filter
- Remove OTC medicines filter OTC medicines (12)
- Other therapeutic goods (1) Apply Other therapeutic goods filter
- Prescription medicines (7) Apply Prescription medicines filter
- Scheduling (56) Apply Scheduling filter
- Remove Therapeutic Goods Administration (TGA) filter Therapeutic Goods Administration (TGA) (2)
- Therapeutic goods regulation (3) Apply Therapeutic goods regulation filter
- (-) Remove Labelling/Packaging filter Labelling/Packaging
- (-) Remove Biologicals filter Biologicals
- (-) Remove Cosmetics filter Cosmetics
- (-) Remove Advertising filter Advertising
- (-) Remove Therapeutic Goods Administration (TGA) filter Therapeutic Goods Administration (TGA)
- (-) Remove OTC medicines filter OTC medicines
Priority Review pathway for biologicals: feasibility, potential eligibility criteria and determination process
Closed on 28 March 2022
Consultation on potential regulatory options for 'export only' biologicals
Closed on 20 December 2021
Proposed changes to Required Advisory Statements for Medicine Labels (RASML): Melatonin
Closed on 17 September 2021
Proposed changes to Required Advisory Statements for Medicine Labels (RASML): Triptans
Closed on 17 September 2021
Proposed changes to Required Advisory Statements for Medicine Labels (RASML): Mometasone
Closed on 17 September 2021
Proposed minor changes to Required Advisory Statements for Medicine Labels (RASML): Chlorhexidine, hydrocortisone, ibuprofen
Closed on 17 September 2021
Proposed improvements to the Therapeutic Goods Advertising Code
Closed on 18 June 2021
Proposed changes to Required Advisory Statements for Medicine Labels (RASML): Methyl salicylate
Closed on 18 May 2021